NCT05678335尚未招募2 期
Tacrolimus for Mild Thrombocytopenia in Sjogren's Syndrome
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 54
- 主要终点
- Complete response rate
研究概览
简要总结
This 12-week randomized, open-label study evaluates the efficacy and safety of Tacrolimus for Sjogren's syndrome patients with thrombocytopenia.
详细描述
This study evaluates the efficacy and safety of Tacrolimus for the treatment of thrombocytopenia in Sjogren's syndrome patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of Sjogren's syndrome according to the 2002 revised American-European Consensus Group (AECG) criteria.
- •Baseline platelet counts within 30-80×109/L.
排除标准
- •Concomitant other systemic autoimmune diseases.
- •Severe complications of Sjogren's syndrome.
- •Abnormal laboratory tests such as: white blood cell count <2.5x10^9/L, hemoglobin <80 g/L, AST/ALT >1.5 ULN, serum creatine > 1.5 mg/dL.
- •Received glucocorticoids, immunosuppressants, or biological agents within 3 months.
- •Active acute or chronic infections.
- •History of malignancy.
- •Pregnancy or breastfeeding.
研究组 & 干预措施
Hydroxychloroquine monotherapy
Placebo Comparator
Oral hydroxychloroquine 200mg twice daily for 12 weeks.
干预措施: Hydroxychloroquine (Drug)
Tacrolimus monotherapy
Experimental
Oral tacrolimus 1-2mg twice daily for 12 weeks.
干预措施: Tacrolimus (Drug)
结局指标
主要结局
Complete response rate
时间窗: week 12
Complete response (platelet counts \> 100×10\^9/L) rates at week 12.
次要结局
- ESSDAI improvement(week 12)
- ESSPRI improvement(week 12)
- Complete response rate(week 4 and week 8)
研究者
Wen Zhang
Prof.
Peking Union Medical College Hospital
相似试验
尚未招募
2 期
Tacrolimus Plus Glucocorticoid for Severe Thrombocytopenia in SSSjogren Syndrome With Other Organ InvolvementNCT05694130Peking Union Medical College Hospital110
已完成
2 期
Pilot Study of Thalidomide to Treat Sjogren's SyndromeSjogren's SyndromeXerostomiaNCT00001599National Institute of Dental and Craniofacial Research (NIDCR)28
已完成
2 期
Efficacy and Safety of Eltrombopag + Tacrolimus in Chinese Refractory or Relapsed Aplastic Anemia PatientsDrug EffectAplastic AnemiaNCT04403321Peking Union Medical College Hospital114
已完成
4 期
A Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent Inhalation Aerosol in COPD Patients.Pulmonary Disease, Chronic ObstructiveNCT00359788Boehringer Ingelheim349
进行中（未招募）
3 期
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)Hepatocellular CarcinomaNCT05904886Hoffmann-La Roche687